InspireMD (NSPR) Shares are Down -19.31%

InspireMD (NSPR) : During the past 4 weeks, traders have been relatively bearish on InspireMD (NSPR), hence the stock is down -39.43% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -19.45% relative to the S&P 500. The 4-week change in the price of the stock is -39.75% and the stock has fallen -19.31% in the past 1 week.

The stock has recorded a 20-day Moving Average of 28.02% and the 50-Day Moving Average is 44.34%.The 200 Day SMA reached 80.4%


InspireMD (NYSEMKT:NSPR): The stock opened in the green at $0.082 on Friday, but the bulls found it difficult to push the prices higher. The stock reached a high of $0.0832 and a low of $0.073 for the day. The stock did not find buyers even at the lows and closed at $0.0823 recording a loss of -0.24%. 2,440,486 shares exchanged hands during the trading day. The stock had closed at $0.0823 in the previous days trading.

InspireMD, Inc. is a medical device company. The Company is focused on the development and commercialization of its MicroNet stent platform technology for the treatment of complex coronary and vascular disease. The Companys MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. The Companys MGuard coronary products combining MicroNet and a bare-metal stent (MGuard Prime Embolic Protection Stent (EPS)) are marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The Companys second product CGuard carotid embolic prevention system (EPS) combines MicroNet and a self-expandable nitinol stent in a single device to treat carotid artery disease. The Company is also developing a pipeline of other products and additional applications by leveraging its MicroNet technology.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.